BIOLASE (NASDAQ:BIOL) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL) in a report released on Thursday. The brokerage set a “sell” rating on the medical technology company’s stock.

BIOLASE Price Performance

BIOLASE stock opened at $0.01 on Thursday. BIOLASE has a fifty-two week low of $0.02 and a fifty-two week high of $1.94. The company has a market cap of $450,994.50, a P/E ratio of 0.00 and a beta of 0.67. The firm’s 50 day simple moving average is $0.01 and its 200-day simple moving average is $0.01.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.